Die irreversible Elektroporation (IRE) ist eine neuartige Gewebeablationstechnik zur bildgesteuerten lokoregionalen Tumortherapie. Im Gegensatz zu thermischen Methoden stellt die IRE ein überwiegend nicht-thermisches Ablationsverfahren dar, dessen Wirksamkeit folglich nicht durch den "heat sink effect" limitiert wird. Ein weiterer Vorteil ist die Anwendbarkeit der IRE in Tumoren, welche unmittelbar an sensiblen Strukturen wie Gefäßnerven-Bahnen und Gallenwegen lokalisiert sind. In bisherigen Studien konnte die Durchführbarkeit der IRE in verschiedenen Tumorentitäten erfolgreich demonstriert werden. Hinsichtlich der klinischen Wirksamkeit konnten insbesondere für die Ablation in Leber-, Pankreasund Prostatatumoren erste vielversprechende Ergebnisse verzeichnet werden. Komplikationen waren insgesamt selten und traten am häufigsten durch Verletzung von Gallengängen oder Blutgefäßen und dabei eher bei IRE in Pankreas-als in Leber-oder Prostatatumoren auf. Die praktische Ausführbarkeit von IRE in der Niere wurde bisher nur in wenigen Studien gezeigt. Für den Einsatz des Verfahrens bei pulmonalen Raumforderungen konnten aufgrund eingeschränkter Durchführbarkeit bisher keine Vorteile gezeigt werden. Die folgende Übersichtsarbeit stellt eine strukturierte Zusammenfassung zum Stand der klinischen Forschung bereit und diskutiert potentielle Indikationen für IRE in der minimalinvasiven Ablationstherapie solider Tumoren. Kernaussagen: ▶ Präklinisch gewonnene Erkenntnisse wurden erfolgreich in die klinische Anwendung der IRE übertragen. ▶ Durch nicht-thermische Ablation können "heatsink-effect" und Koagulationsverletzungen unbeteiligter Strukturen umgangen werden.
Abstract ▼ Irreversible electroporation (IRE) is the latest in the series of image-guided locoregional tumor ablation therapies. IRE is performed in a nearly nonthermal fashion that circumvents the "heat sink effect" and allows for IRE application in proximity to critical structures such as bile ducts or neurovascular bundles, where other techniques are unsuitable. IRE appears generally feasible and initial reported results for tumor ablation in the liver, pancreas and prostate are promising. Additionally, IRE demonstrates a favorable safety profile. However, site-specific complications include bile leaking or vein thrombosis and may be more severe after pancreatic IRE compared to liver or prostate ablation. There is limited clinical evidence in support of the use of IRE in the kidney. In contrast, pulmonary IRE has so far failed to demonstrate efficacy due to practicability limitations. Hence, this review will provide a state-of-the-art update on available clinical evidence of IRE regarding feasibility, safety and oncologic efficacy. The future role of IRE in the minimally invasive treatment of solid tumors will be discussed.
Key points:
Introduction ▼ Ablative therapies have become well accepted locoregional approaches in the treatment of solid tumors [1] . The latest addition to the family of ablative techniques is irreversible electroporation (IRE), which was first introduced as a novel minimally invasive ablative modality in 2005 [2] . IRE employs short electrical pulses to permanently permeabilize cell membranes resulting in homeostatic dysbalance and eventual cell death. This mechanism was extensively studied in preclinical settings where IRE has been proven to effectively ablate substantial amounts of tumor tissue. However, reported clinical experience remains sparse and mainly non-standardized. This narrative review will provide a clinical synopsis of IRE ablation in the treatment of solid tumors. With a focus on IRE applications in the liver, pancreas, lung, kidney and prostate, achievements and limitations of non-thermal ablation in the field of image-guided therapies will be exemplified.
Technical principles of IRE
Given the term "electroporation", the mechanistic phenomenon behind IRE is based on an increase of cell membrane permeability through the application of high-voltage electrical currents. Therefore, IRE employs the positioning of adjustable needle electrodes (18G) in or around the targeted tumor under image guidance, preferably using ultrasound (US) or computed tomography (CT). Microsecond electrical fields are utilized to alter the transmembrane potential inducing irreversible instabilities in the cell membranes. As a result, nanoscale pores (80 -490 nm) are formed and followed by a disruption in cell homeostasis. Eventually, cell death in IRE treatment zones occurs homogenously with a narrow transitional zone [2, 3]. "Irreversible" refers to definite cell ablation that prevents the resealing of membranes after treatment and achieves permanent permeabilization. From a clinical perspective, the implementation of irreversible ablation essentially depends on the proper setting of critical parameters such as the modifiable altitude, duration, shape, number and frequency of applied pulses [3 -5]. IRE has been proven to effectively ablate tumor cells in vitro [3] as well as in vivo [6 -9] with an acceptable toxicity profile. In this setting, two major methodic advantages were identified that spur on research in the field of IRE. Firstly, as opposed to the majority of ablative modalities, IRE has the remarkable characteristic of being nearly non-thermal [2, 6, 10]. Subsequently, the effect of blood flow on IRE is negligible and there will be no reduction of ablative efficacy contiguous to blood vessels through the "heat sink effect" [2, 10, 11] . This marks a momentous contrast to thermal regimes, which are substantially influenced by perfusion [12] and also limited in their application near heat-sensitive structures such as bile ducts, nerves or intestinal loops [13] .
Secondly, it is of major importance for all locoregional therapies to achieve precise and well-controlled ablation of the tumor and a peritumoral safety margin while sparing healthy surrounding structures. Hence, IRE is a beneficial modality as targeted cell ablation occurs selectively with preservation of connective tissue, adjacent nerves and blood vessels within the sharply delineated ablation zone [14, 15] . Subsequently, treatment-related complications are minimized and intact vasculature accelerates resolution of the lesions [4, 16, 17] .
Clinical Considerations
IRE is performed percutaneously or via open surgical or laparoscopic access. Usually, tumors assigned for IRE are declared unresectable and not suitable for thermal ablation due to the proximity to sensitive structures (e. g. nerves or bile ducts) [7] . Preprocedural imaging data are transferred to a pulse generator that calculates the position and number of probes based on a computer algorithm [18] . In the majority of trials, IRE was performed using NanoKnife (Angiodynamics) and configurations were set according to standard algorithms provided by the manufacturer. Usually, a series of 90 high-speed currents is administered with a duration of 20 -100 microseconds and up to 3000 V [18, 19] . Consequently, a typical session takes less than 1 minute to treat a tumor 3 cm in diameter and approximately 3 to 5 min when additional ablations are performed [17] . Despite the short ablation time, general anesthesia is mandatory as complete neuromuscular blockade is required to avoid muscle contractions triggered by the applied currents [16] . Hence, apart from site-specific complications, IRE procedures include all risks related to anesthesia [16, 19] . In order to prevent current-related ventricular arrhythmia as a potentially severe complication, ablation pulses should be applied in an electrocardiogram (ECG)gated fashion, except for prostate ablation [16, 19] . A recent prospective analysis of treatment-related adverse events included 28 patients who were treated with open (n = 13) or percutaneous (n = 15) IRE for different abdominal tumors. Despite ECG synchronization, cardiac arrhythmia occurred in two patients during laparotomy (n = 1, ventricular extrasystole) and percutaneous pancreatic IRE (n = 1, bigeminy) but appeared to be mild without hemodynamic relevance and was self-limiting within one day [20] . In terms of follow-up, standardized criteria have not yet been defined to predict successful ablation. However, in a number of clinical trials, tumor response to IRE was determined based on the Response Evaluation Criteria in Solid Tumors (RECIST) with welldemarcated hypoattenuating ablation zones indicating successful interventions [21, 23] and new or persistent enhancement indicating incomplete ablation or local recurrence (LR) [18, 19, 21] . 
Clinical Results

▼
In order to provide a status quo overview of the clinical experience reported for IRE, the bibliographic database of Pubmed was screened for prospective and retrospective original articles using the search terms "IRREVERSIBLE ELECTROPORATION", "NON-THERMAL ABLATION" and "ABLATION" in combination with synonyms for each tumor entity described below.
Liver Thomson et al. were the first to investigate the safety and efficacy of IRE in 38 patients, 25 of whom presented with primary or secondary liver tumors (range: 1 -5 cm). After 63 IRE ablations, the complete response (CR) rate for hepatocellular carcinoma (HCC) was 83.3 % whereas CR in colorectal liver metastases (CRM) was observed in 50 % according to RECIST on 1-and 3-month followup imaging. Lesions ≥ 5 cm did not show significant tumor re-sponse [21] . Similarly, another prospective trial included 11 patients for percutaneous IRE in 18 HCC lesions with a diameter of 1.0 -6.1 cm. Lesions ≤ 3 cm required 4 ablations with repositioned needles, while bigger lesions were treated with 16 ablations per session on average. Moreover, 6 patients had received repeated treatment due to LR and intrahepatic metastases. Except for transient postprocedural pain (64 %), no complications were observed in this study. At 6 mo, response evaluation revealed CR in a total of 72 % and 93 % of tumors ≤ 3 cm and the local progression-free survival (PFS) was 18 ± 4 mo and the distance PFS was 14 ± 6 mo [24] . The previous findings are also in line with the preliminary results of a prospective multicenter phase II trial conducted by Lencioni et al. using IRE for the treatment of early stage HCC. According to RECIST, 23 out of a total of 29 tumors showed CR (79 %). Within 1 mo of follow-up, complications were rare including one case of transient hepatic decompensation and one hematothorax [25] . In two prospective studies, IRE was performed either via percutaneous or surgical access. In the first trial, 44 patients with centrally located HCCs (n = 14), CRMs (n = 20) and other secondary liver malignancies (n = 10) (range: 2.1 -2.7 cm) were included. Technical success was achieved in 100 % of HCCs and 95 % of CRM lesions. CR was reported in 100 % of cases according to RECIST with a local PFS of 97.4 %, 94.6 % and 59.5 % at a 3-, 6-and 12-month follow-up, respectively. The authors observed a trend towards higher recurrence rates in tumors > 4 cm as well as for percutaneous probe placement [18] . The second series included 13 patients with HCC (n = 5), CRM (n = 6) and recurrent intrahepatic cholangiocarcinoma (n = 2) and an average tumor size of 1.5 ± 0.5 cm. Surgical access for IRE was combined with hepatic resection (n = 6). Except for one procedure, IRE was technically successful without treatment-related complications. Three ablations (23 %) turned out to be incomplete within 6 mo, all of which were after percutaneous approaches. Moreover, LR was observed in two other patients with tumors > 2 cm and in one site of a patient with bifocal ablation. Hence, the authors claim that percutaneous access, diameters exceeding 2 cm and CRM as an indication are associated with a higher risk of local failure [26] (• ▶ Table 1 ).
A number of retrospective studies focused on the effect of IRE on central hepatic structures [27, 28] . In this setting, Kingham et al. analyzed imaging-based tumor response and adverse events in 28 patients after IRE. The lesions appeared to have a small median size of 1 cm (range: 0.5 -5 cm) and were located < 1 cm from a major hepatic vein or portal pedicle. However, the overall morbidity was low with 3 % including a single event of arrhythmia and portal vein thrombosis (PVT). As for efficacy, one patient presented with stable disease (SD) (1.9 %) at 6 mo and LR was observed in three patients (5.7 %) [29] .
Overall, research on IRE in hepatic malignancies has been successfully initiated and multifaceted clinical evidence is primarily available for HCC and CRM (• ▶ Fig. 1 ). With regards to this, IRE demonstrated favorable toxicity even when performed in proximity to sensitive structures and current literature suggests technical practicability and beneficial clinical outcomes, particularly for surgical access. However, lesion size remains a limiting factor for the efficacy of IRE in this setting that could possibly be countered by optimizing the number and configuration of needles.
Pancreas
Bagla et al. reported on the first case of IRE ablation in a single patient who was successfully treated for unresectable locally advanced pancreatic carcinoma (LAPC) [30] . Soon afterwards, the first prospective series was conducted to examine the safety and feasibility of IRE in 27 patients with LAPC and celiac plexus invasion who had all received previous therapies. Tumors with an average diameter of 3 cm were located in the pancreatic head (n = 15) and body (n = 12 [32] . Similarly, in a recent large multicenter prospective trial, 200 patients were included to investigate the efficacy of multimodal treatment approaches including IRE for the therapy of stage III LAPC. All patients received induction chemotherapy or chemoradiation followed by IRE alone (n = 150) or with consecutive pancreatic resection (n = 50). The median OS was 24.9 mo (range: 4.9 -85 mo) and 6 patients (3 %) developed LR within a median follow-up of 29 mo. Compared to historical reports, the authors suggest a benefit for combined treatment regimens including IRE as compared to chemotherapy alone [33] . Another large prospective multicenter investigation including 107 patients with locally advanced hepatic (n = 42) as well as pancreatic (n = 37) tumors with a small size of < 0.5 cm was published by the same group. Probes were placed percutaneously (n = 33) or surgically (n = 84) for a median number of two lesions. In terms of efficacy, a local PFS of 12.7 mo in total was reported. High grade adverse events occurred in 4.19 % of cases including biliary complications and bleeding [34] . The efficacy of IRE was recently investigated in an intraoperative setting with the use of a prospective database. 48 patients with LAPC < 3.5 cm and a history of previous treatments were scheduled for pancreatic resection. Of a total of 44 adverse events after ablation, 5 were possibly IRE device-related and included bile leakage and PVT. No LR was observed at the 90-day follow-up. However, at 24 mo, 28 patients (58 %) showed LR and metastatic disease. The median PFS and OS were reported as 11 and 22.4 mo, respectively [35] . A smaller prospective single-center study was conducted in 10 patients with LAPC (range: 2.5 -3.9 cm) of the pancreatic head (n = 7) and body (n = 3) refractory to previous treatments. (PFS of 6 and OS of 11 mo), a prognostic benefit for IRE became apparent [39] . To sum up, IRE has repeatedly proven to prevent recurrence and hold back local progression with a prognostic benefit in patients with LAPC (• ▶ Fig. 2) . It is particularly encouraging that some studies report cases of patients who could be transferred to resection after IRE. Major complications included PVT and bile leaks but the overall morbidity was tolerable.
Lung
Besides the liver and kidney, IRE was also performed in the lung in 3 patients (CRM, breast cancer metastasis, non-small cell lung cancer (NSCLC)) in a prospective setting. This early case series by Thomson et al. examined the efficacy and safety of the procedure as described earlier in this review. However, as opposed to liver tumors, all patients presented with PD at a 1-and 3-month follow-up according to RECIST. As revealed by biopsy, treatment failure occurred as a result of incomplete ablation. 2 patients developed pneumothoraces related to central lung ablation that resolved spontaneously. 1 patient was lost within the follow-up period [21] . Another case series reported on the IRE treatment of 2 patients with lung malignancies. The first patient presented with a hilar sarcoma metastasis (2.3x2.4x1.7 cm) and the second patient had suprahilar non-small cell lung cancer (NSCLC; 2.1x1.9x2.1 cm) and comorbid radiogenic pulmonary fibrosis. At a 6-and 2month follow-up, CT and PET/CT imaging revealed LR and even PD similar to the previously described study. Subsequently, the authors postulated the failure of IRE in lung parenchyma due to limited feasibility [40] . The first controlled prospective study was a recent multicenter phase II trial (ALICE) to investigate the safety and efficacy of IRE in primary and secondary lung malignancies, mainly CRM (n = 13). Initially, 36 patients with previous treatments but normal lung function were included but the study was terminated early after the treatment of 23 patients. Treated target lesions measured a median diameter of 1.6 cm (range: 0.8 -2.7 cm). As for major complications, 11 patients developed pneumothoraces, 8 of which required chest tubes. Regarding efficacy, 7 patients showed CR (39 %), 1 had partial remission (4 %), 1 had SD (4 %) and 14 developed PD (61 %) at a 3-month follow-up using CT and PET/CT. As precise parallel probe alignment was limited by the thoracic cavity, effective ablation could not be guaranteed and IRE eventually failed to demonstrate efficacy in this setting. Moreover, needle tract seeding was observed in 3 cases (13 %) [41] . Mainly due to fundamental feasibility limitations, IRE has so far failed to prove efficacy in lung parenchyma. Common complications included pneumothoraces in numerous patients.
Kidney
Pech et al. reported the first-in-man phase I clinical trial to examine the feasibility and safety of intraoperative IRE in 6 patients with local renal cell carcinoma (RCC) who were scheduled for curative tumor resection. IRE was performed approximately 15 minutes prior to surgery. Except for one minor arrhythmia, no adverse effects were recorded within the short-term follow-up period of 12 weeks. However, immediate biopsy could not demonstrate cell death in the specimens [42] . A recent pilot study ("IRENE trial") to investigate the histopathological effects of IRE included 3 patients with localized RCC (T1a; range: 1.5 -1.7 cm) in a central (n = 1) or peripheral (n = 2) loca-tion. Focal IRE was performed in a percutaneous fashion 4 weeks prior to renal resection. Contrary to an expected homogenous ablation zone, ex vivo analyses revealed structuring of the treated area with central necrosis surrounded by tissue that was secondarily damaged by nutritive deprivation. Additionally, 2 resected tissues demonstrated residual tumor satellites within the ablation zone [43] . Thomson et al. performed IRE of 11 renal tumors (RCC, n = 11; other tumors, n = 4) with a median tumor size of 2.7 (range: 1.6 -5.3 cm). The primary efficacy was 45 % and CR was achieved in RCC lesions. The authors reported on 1 case of accidental adrenal ablation followed by severe hypotension for 2 mo and hematuria in 2 patients after central IRE [21] . However, IRE for the treatment of RCC proved feasible and safe in the presented trial but prospective efficacy studies on IRE are warranted.
Prostate
Onik et al. reported the first case series including 16 patients with unifocal prostate cancer of varying Gleason scores. Based on preprocedural biopsies, the cancer loci were targeted under transrectal US (TRUS) guidance (• ▶ Fig. 3 [45] .
With special regard to the technical success of ablation procedures, a multicenter prospective trial reporting on 16 men who were treated with IRE for localized prostate cancer 4 weeks prior to radical prostatectomy was recently published. Within the short follow-up period, no serious adverse events occurred. The histopathological examination of the harvested tissue revealed complete necrosis and fibrosis of the ablation zone which corresponded well with the configuration of needle placement for focal (n = 6) or extended (n = 10; ≥ 4 electrodes) IRE [46, 47] Table 3 ).
In conclusion, clinical experience with the use of IRE in prostate cancer is relatively limited but further results of prospective analyses in larger cohorts are forthcoming [52] . So far, safety reports on transperineal IRE state favorable safety, and clinical followups demonstrate preserved continence and potency. However, prospective oncologic efficacy studies are sorely needed to finally Fig. 4, 5 ).
Conclusion and Future Directions
▼ Preclinical findings of IRE have been translated into clinical settings. At present, IRE appears to be filling a niche for the ablation of tumors in proximity to critical structures such as the hilus region or large vessels where either the heat sink effect or collateral damage constitute a concern for thermal ablation and resection. With respect to efficacy, the results of IRE found in this review appear promising in the liver, pancreas, and prostate where the overall morbidity is also tolerable. In terms of safety, no attributed mortality has been reported so far and mainly mild transient side effects such as postprocedural pain similar to radiofrequency ablation occur [53] . On the contrary, there is no evidential benefit of IRE in the lung parenchyma. In this setting, feasibility is limited and pneumothoraces occur as frequent potentially severe complications. Regarding renal IRE, no definite conclusion can be drawn here due to limited data. However, Pech et al. reported successful performance of IRE in the kidney with a favorable safety profile [41] . Overall, one of the shortcomings of IRE today remains the absence of clinically validated protocols to be used in different tumor entities. Current literature only provides a low level of evidence as the presented studies are mostly small case series or heterogeneously designed reports without control groups. IRE has so far been applied with palliative intent but may also be a feasible adjuvant procedure in resectable tumors. With regard to this, randomized controlled trials are required to determine IRE indication in a continuously growing armamentarium of locoregional therapies. 
